Vanguard Group Inc Altimmune, Inc. Transaction History

Vanguard Group Inc

$5.37 Trillion
Q1 2025

A detailed history of Vanguard Group Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,407,462 shares of ALT stock, worth $23.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,407,462

Previous 4,431,612 0.54%

Holding current value

$23.9 Million

Previous $32 Million 31.03%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$5.0 - $7.45 $120,750 - $179,917	-24,150 Reduced 0.54%	4,407,462 $22 Million
Q4 2024 Feb 11, 2025	SELL	$6.02 - $9.85 $3.32 Million - $5.44 Million	-552,246 Reduced 11.08%	4,431,612 $32 Million
Q3 2024 Nov 13, 2024	BUY	$5.5 - $8.1 $424,842 - $625,676	77,244 Added 1.57%	4,983,858 $30.6 Million
Q2 2024 Aug 13, 2024	BUY	$5.91 - $10.23 $10.5 Million - $18.2 Million	1,777,886 Added 56.82%	4,906,614 $32.6 Million
Q1 2024 May 10, 2024	SELL	$8.22 - $13.81 $3.64 Million - $6.12 Million	-443,244 Reduced 12.41%	3,128,728 $31.9 Million
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $487,228 - $2.65 Million	227,677 Added 6.81%	3,571,972 $40.2 Million
Q3 2023 Nov 14, 2023	BUY	$2.4 - $3.45 $91,975 - $132,214	38,323 Added 1.16%	3,344,295 $8.7 Million
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $2.65 Million - $4.59 Million	768,251 Added 30.27%	3,305,972 $11.7 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $22,211 - $89,215	5,301 Added 0.21%	2,537,721 $10.7 Million
Q4 2022 Feb 10, 2023	BUY	$8.74 - $16.45 $4.42 Million - $8.31 Million	505,378 Added 24.93%	2,532,420 $41.7 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $3.22 Million - $6.76 Million	301,496 Added 17.47%	2,027,042 $25.9 Million
Q2 2022 Aug 12, 2022	SELL	$3.94 - $11.77 $359,993 - $1.08 Million	-91,369 Reduced 5.03%	1,725,546 $20.2 Million
Q1 2022 May 13, 2022	BUY	$5.9 - $9.45 $490,644 - $785,861	83,160 Added 4.8%	1,816,915 $11.1 Million
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $846,388 - $1.22 Million	97,398 Added 5.95%	1,733,755 $15.9 Million
Q3 2021 Nov 12, 2021	BUY	$8.43 - $16.81 $423,725 - $844,937	50,264 Added 3.17%	1,636,357 $18.5 Million
Q2 2021 Aug 13, 2021	BUY	$9.85 - $16.46 $15.6 Million - $26.1 Million	1,586,093 New	1,586,093 $15.6 Million

Others Institutions Holding ALT

# of Institutions

202

Shares Held

37.6M

Call Options Held

Put Options Held

1.69M

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $266M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Altimmune, Inc. Transaction History